On Thursday, Shares of Opko Health, Inc. (NYSE:OPK), surged 2.54% to $9.28.
Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal has formerly received planned investments from Teva Pharmaceuticals, OPKO Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group.
Cocrystal Pharma, Inc. (COCP), declared that its late-breaking abstract was accepted for a poster presentation at The Liver Meeting, the annual meeting of the American Association of the Study of Liver Diseases (AASLD) in San Francisco, November 13-17. The abstract, entitled, “Preclinical characterization of CC-31244, a potent, pan-genotypic nonnucleoside NS5B polymerase inhibitor (NNI) for the treatment of chronic hepatitis C”, will be presented by Dr. Sam Lee, President, on Monday the 16th at 12:30 pm.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
On other hand, Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX), surged 65.17% to $27.93, hitting its highest level.
Five Prime Therapeutics, will host a conference call and live audio webcast recently, October 15 at 8:30 a.m. (ET)/5:30 a.m. (PT) to discuss the new worldwide license and partnership agreement signed with Bristol-Myers Squibb for FPA008, Five Prime’s CSF1R antibody program.
The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of the company’s website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 60918903.
The most recent price of Five Prime Therapeutics, is now at a discount to the 12-month high of $28.48 hit on Oct 15, 2015. The last price is at a premium to the 52-week low of $11.78 suffered on Oct 23, 2014. The stock is up 6.64% in this year through last close.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes.
